Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Biogen Inc.
Nieuws
Biogen
BIIB
NAS
: BIIB
| ISIN: US09062X1037
8/06/2023
308,88 USD
(+1,31%)
(+1,31%)
8/06/2023
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
16 mei 2023 ·
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
· Persbericht
25 april 2023 ·
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
· Persbericht
31 maart 2023 ·
Additional Detailed Analyses From Phase 2 Study 201 Of Lecanemab Published As Three Papers In Peer-Reviewed Journals
· Persbericht
31 maart 2023 ·
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
· Persbericht
31 maart 2023 ·
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
· Persbericht
29 maart 2023 ·
New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
· Persbericht
23 maart 2023 ·
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
· Persbericht
16 maart 2023 ·
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
· Persbericht
8 maart 2023 ·
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
· Persbericht
6 maart 2023 ·
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
· Persbericht
6 maart 2023 ·
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
· Persbericht
28 februari 2023 ·
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
· Persbericht
6 februari 2023 ·
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
· Persbericht
30 januari 2023 ·
Lecanemab Receives Priority Review Status in Japan
· Persbericht
27 januari 2023 ·
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
· Persbericht
27 januari 2023 ·
Marketing Authorization Application For Lecanemab As Treatment For Early Alzheimer's Disease Accepted By European Medicines Agency
· Persbericht
16 januari 2023 ·
Eisai Files Marketing Authorization Application For Anti-Amyloid-Beta Protofibril Antibody Lecanemab For Early Alzheimer's Disease In Japan
· Persbericht
11 januari 2023 ·
Eisai Submits Marketing Authorization Application For Lecanemab As Treatment For Early Alzheimer's Disease In Europe
· Persbericht
7 januari 2023 ·
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
· Persbericht
6 januari 2023 ·
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe